Please ensure Javascript is enabled for purposes of website accessibility

Why Medifast Shares Plunged

By Jeremy Bowman – Updated Nov 17, 2016 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this meaningful? Or just another movement?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of weight-loss specialist Medifast (MED -0.26%) were looking unseemly to investors today, falling as much as 16% on news that its acting CFO would be resigning after just a month on the job.

So what: Medifast said acting CFO Edward Powers -- whose last day with the company will be Jan. 4 -- was leaving to "pursue other interests," and a spokesperson added that he found a job with another company. Powers was standing in place of former CFO Brendan Connors, who had resigned on Nov. 13, also to "pursue other interests."

Powers had joined Medifast in 2011 as senior controller, and will be replaced by Joseph Kelleman, director of finance, supply chain. The company will continue its search for a permanent CFO.

Now what: If Powers' departure is nothing more than his finding a better opportunity elsewhere, then the market is overreacting here. Medifast's weight-loss/health supplement sector has been getting hammered since Bill Ackman presented his argument for shorting Herbalife last Thursday, so investors may be a little skittish about anything fishy in the industry. Shares of Medifast fell 6% the day after Ackman's presentation, but there's no reason to think Powers' resignation is anything more than what the company says it is. Medifast notably does not employ the multi-level marketing strategy that Herbalife uses, and which has attracted criticism from Ackman and others, so it is largely safe from those concerns.

Stay on top of this developing story by adding Medifast to My Watchlist.

Fool contributor Jeremy Bowman has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Medifast, Inc. Stock Quote
Medifast, Inc.
$109.37 (-0.26%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.